Immunotherapy for Resectable Non-Small Cell Lung Cancer in Older Adults: Current Evidence

For patients aged 65 and older with resectable non-small cell lung cancer (NSCLC), adding immunotherapy to standard surgical care likely reduces the amount of residual cancer and delays disease recurrence. However, current clinical data suggests that these treatments—which help the immune system identify and target malignant cells—do not significantly extend overall survival in this age group, according to a 2026 systematic review published in the Cochrane Database of Systematic Reviews.

Understanding Resectable NSCLC in Older Populations

Non-small cell lung cancer accounts for approximately 85% of all lung cancer diagnoses, with a median age of 71 at the time of discovery. “Resectable” refers to tumors that have not spread beyond the lung and are considered suitable for surgical removal. While surgery remains the primary treatment, the risk of recurrence is significant, with studies indicating that between 30% and 55% of patients eventually succumb to the disease. Because the aging process can diminish immune function—a phenomenon known as immunosenescence—clinicians have long sought to determine if immunotherapy, when used alongside or instead of traditional chemotherapy, remains effective for older patients.

Clinical Findings on Treatment Efficacy

The 2026 Cochrane systematic review synthesized data from 11 clinical trials involving 3,152 participants aged 65 and older. The researchers evaluated various treatment protocols, including immunotherapy administered alone or in combination with chemotherapy, either before or after surgical intervention. The analysis compared these regimens against placebos or standard-of-care chemotherapy alone.

The findings indicate that immunotherapy provides a measurable benefit in the immediate perioperative period:

• Tumor Reduction: Immunotherapy increases the likelihood of reducing tumor burden prior to surgery.
• Recurrence Delay: The treatment likely delays the time it takes for cancer to return following the initial operation.
• Survival Impact: Evidence suggests that these therapies likely make little to no difference in overall patient survival rates for this specific age demographic.

Limitations and Future Research Needs

Despite the promise of immunotherapy in managing localized lung cancer, the researchers highlighted substantial gaps in the current evidence base. The confidence level for these findings is generally categorized as “moderate,” largely due to inconsistencies in how individual studies were conducted.

A critical limitation noted by the authors is the lack of data regarding patient well-being and potential adverse effects. Only one of the 11 studies included in the review provided comprehensive data on treatment-related harms. Because the elderly population is highly diverse, clinicians emphasize that chronological age alone is an insufficient metric for determining treatment candidacy. More long-term, high-quality data are required to establish whether the clinical benefits of immunotherapy—such as delayed recurrence—outweigh the potential risks of side effects in patients over 65.

Summary of Evidence

As of July 3, 2025, this systematic review represents the most current assessment of perioperative immune checkpoint inhibitors in the elderly. Future clinical trials must prioritize standardized reporting of adverse events and quality-of-life metrics to provide a clearer picture for oncologists and geriatric patients navigating treatment decisions.